Start up. Grow up. Succeed.

News 2016

4SC AG: Dr Daniel Vitt to step down as CDO CSO and from the Management Board at the end of 2016 | Dr Frank Hermann promoted to CDO and Dr Roland Baumgartner to CSO

4SC AG (4SC, FSE Prime Standard: VSC) today announced that Dr Daniel Vitt and the Supervisory Board of 4SC have agreed that Daniel Vitt will step down as Chief Development Officer and Chief Scientific Officer (CDO/CSO) as well as from the Management Board of 4SC as of 31 December 2016.

Astellas to Acquire Ganymed Pharmaceuticals -Acquisition Would Expand Astellas' Oncology Pipeline with Antibody in Late-Stage -

Tokyo and Mainz, October 28, 2016 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s shareholders have entered into an agreement for Astellas to acquire Ganymed.

Venture Lounge at Merck Innovation Center elects 3 winners

On invitation by CatCap Corporate Finance, Merck KGaA, SHS Gesellschaft für Beteiligungsmanagement, Paul Hartmann AG and HTGF , around 60 representatives of the Venture Capital scene met at Merck's innovation center in Darmstadt.

Expanding into the global 3D printing market: All3DP successfully closes Series A round

All3DP GmbH, operator of a fast growing English-language Internet platform for 3D printing, has completed seven-figure Series A financing round.

Immunic acquires 4SC’S Immunoloqy portfolio

Immunic acquires two promising drug development programs with validated targets known to be relevant in various immune and autoimmune diseases

4SC sells immunology portfolio to Immunic

Continuing to focus the epigenetics strategy on key oncology assets

Venture Lounge "Life Science & MedTech" on the 25th October 2016

Together with Merck KGaA, CatCap is hosting a Venture Lounge for Life Sciences in Darmstadt on the 25th of October 2016.

BioNTech to enter into worldwide strategic collaboration with Genentech to develop individualized mRNA cancer therapies

Collaboration will draw upon Genentech’s leading position in cancer immunotherapy and BioNTech’s premier clinical mRNA vaccine platform.

Chinese FDA Grants MammaTyper® Innovative Product Status for Expedited Approval

BioNTech Diagnostics GmbH, a fully owned subsidiary of BioNTech AG, and its Chinese partner Shuwen Biotech Co. Ltd. today announced that the Chinese FDA (CFDA) has granted the “Innovative Medical Product” status for MammaTyper®, a real-time PCR kit for breast cancer stratification.

BioNTech AG Receives Emerging Star of the Year Award at the European Mediscience Awards

BioNTech AG, a fully integrated biotechnology company developing individualized cancer immunotherapies is pleased to announce that it was presented with the “Emerging Star of the Year Award” at the European Mediscience Awards 2016.

Ethris Adds Three New Members to its Board of Directors

Leon Chen, Thomas Chalberg and Justin Duckworth Join Ethris' Board to Support Next Stage of Company's Development

AMSilk grows with additional capital - ramp-up of BIOSTEEL(R) production

AMSilk GmbH, the world's first industrial supplier of synthetic silk molecules, has raised new capital through a further financing round.

Former Sandoz CEO joins supervisory board of LEUKOCARE

Dr. Andreas Rummelt, pharma industry expert and former CEO of Sandoz, was elected as new supervisory board member at LEUKOCARE's annual shareholder meeting on July 12th.

BioNTech AG Receives Emerging Star of the Year Award at the European Mediscience Awards

BioNTech AG, a fully integrated biotechnology Company developing individualized cancer immunotherapies is pleased to announce that it was presented with the “Emerging Star of the Year Award” at the European Mediscience Awards 2016.

PIERIS PHARMACEUTICALS ANNOUNCES $16.5 MILLION PRIVATE PLACEMENT

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) announced today that it entered into a securities purchase agreement for a private placement with a select group of institutional investors, including lead investor BVF Partners L.P. and its affiliates as well as existing and new investors.

Siemens enters field of molecular services for oncology

Siemens Healthineers has expanded its diagnostics portfolio with the acquisition of NEO New Oncology AG, Cologne, Germany

Nature publication describes first example of a clinically applicable and systemic mRNA cancer immunotherapy vaccine

Major step towards truly personalized treatment of any cancer

Ethris Publishes Preclinical Data on Musculoskeletal Regeneration Using its Novel mRNA-based Transcript Therapy Approach

MUNICH--(BUSINESS WIRE)--Ethris GmbH, a pioneer in the emerging field of messenger RNA (mRNA) medicine, announced today the publication of a research paper in the peer-reviewed journal “Biomaterials” that underlines the broad therapeutic potential of the company’s proprietary mRNA transcript therapy platform. The paper demonstrates that a modified mRNA construct based on Ethris’ technology coding for the human growth factor BMP-2 (bone morphogenetic protein-2) can induce bone regeneration in three different settings including an established in vivo model for bone healing.

First four companies selected to participate in the German Accelerator Life Sciences program in Cambridge

During the 34th JP Morgan Healthcare Conference, the German Accelerator Life Sciences (GALS) announced the first four companies to participate in its Cambridge-based program. AYOXXA Biosystems, PEPperPRINT, Personal MedSystems, and Sonormed will receive support tailored towards the specific needs of each company for up to 12 months. The scope of these young German companies ranges from treating tinnitus patients with filtered music and preventing stroke via a mobile ECG app to novel platform technologies for medical research and diagnostics.